Microbiology, Genomics, and Clinical Significance of the *Pseudomonas fluorescens* Species Complex, an Unappreciated Colonizer of Humans

Brittan S. Scales, Robert P. Dickson, John J. LiPuma, Gary B. Huffnagle

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Department of Microbiology and Immunology, and Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA

**SUMMARY**

*Pseudomonas fluorescens* is not generally considered a bacterial pathogen in humans; however, multiple culture-based and culture-independent studies have identified it at low levels in the indigenous microbiota of various body sites. With recent advances in comparative genomics, many isolates originally identified as the “species” *P. fluorescens* are now being reclassified as novel *Pseudomonas* species within the *P. fluorescens* “species complex.” Although most widely studied for its role in the soil and the rhizosphere, *P. fluorescens* possesses a number of functional traits that provide it with the capability to grow and thrive in mammalian hosts. While significantly less virulent than *P. aeruginosa*, *P. fluorescens* can cause bacteremia in humans, with most reported cases being attributable either to transfusion of contaminated blood products or to use of contaminated equipment associated with intravenous infusions. Although not suspected of being an etiologic agent of pulmonary disease, there are a number of reports identifying it in respiratory samples. There is also an intriguing association between *P. fluorescens* and human disease, in that approximately 50% of Crohn’s disease patients develop serum antibodies to *P. fluorescens*. Altogether, these reports are beginning to highlight a far more common, intriguing, and potentially complex association between humans and *P. fluorescens* during health and disease.

**INTRODUCTION**

Over the past 15 years, the application of culture-independent methods for microbial identification has revealed a previously unappreciated complexity within human-microbe interactions. One interesting feature is that a number of these studies have identified the bacterium *Pseudomonas fluorescens* as a low-abundance member of the indigenous microbiota of various body sites, including the mouth, stomach, and lungs. *P. fluorescens* has generally been considered nonpathogenic for humans, an assessment dating back to its earliest descriptions, by A. Baader and C. Garre, in *Über Antagonisten unter den Bacterien* (1887) (6):

> The bacillus *P. fluorescens* itself is not pathogenic. A culture applied to animals subcutaneously or injected into the peritoneum does not elicit a reaction. Even when introduced many times into fresh wounds it does not irritate healing by primary intention. Also, ingestion of cultures caused no harm to my stomach or intestines.

However, while far less virulent than *P. aeruginosa*, *P. fluorescens* can cause acute infections (opportunistic) in humans and has been reported in clinical samples from the mouth, stomach, and lungs (Table 1). The most common site of *P. fluorescens* infection is the bloodstream. Most reported cases have been iatrogenic, with bacteremia attributable either to transfusion of contaminated blood products or to use of contaminated equipment associated with intravenous infusions. While...
not suspected of being an etiologic agent of pulmonary disease, we recently reported that *P. fluorescens* is routinely cultured at a low frequency from clinically indicated respiratory samples (3) (Table 2). Perhaps the most intriguing “association” between *P. fluorescens* and human disease is that approximately 50% of Cronh’s disease patients develop serum antibodies to the I2 antigen encoded by *P. fluorescens*, and in some studies, this seroreactivity has correlated with the success of therapies aimed at the microbiome rather than the immune system (18–22). Altogether, these reports and others are beginning to highlight a far more common, and potentially complex, interaction between humans and *P. fluorescens* during health and disease.

The extremely versatile metabolic capabilities of *P. fluorescens* impart this bacterium with the ability to persist in a wide range of environments beyond mammalian hosts (Fig. 1), including soil, the rhizospheres and surfaces of plants, nonsterile pharmaceuticals, showerheads, and even indoor wall surfaces (23, 24). *P. fluorescens* has been studied most widely as an environmental microbe, rather than the immune system (18–22). Altogether, these reports and others are beginning to highlight a far more common, and potentially complex, interaction between humans and *P. fluorescens* during health and disease.

The extremely versatile metabolic capabilities of *P. fluorescens* impart this bacterium with the ability to persist in a wide range of environments beyond mammalian hosts (Fig. 1), including soil, the rhizospheres and surfaces of plants, nonsterile pharmaceuticals, showerheads, and even indoor wall surfaces (23, 24). *P. fluorescens* has been studied most widely as an environmental microbe, rather than the immune system (18–22). Altogether, these reports and others are beginning to highlight a far more common, and potentially complex, interaction between humans and *P. fluorescens* during health and disease.

### PHENOTYPIC TRAITS AND CULTIVATION OF *P. fluorescens*

The bacteria in the *P. fluorescens* species complex are Gram-negative, motile rods that are primarily aerobic, unable to ferment glucose, and chemoorganotrophic and grow at a pH between 4 and 8 (62) (Table 3 and Fig. 3). Isolates of *P. fluorescens* derived from nonmammalian samples have a permissive growth range of 4°C to 37°C (62), while isolates from humans and other mammals have an upper range extending to 37°C (53, 57–59). As of the end of 2013, there were 16 fully sequenced strains from the *P. fluorescens* species complex, and all but one originated from plant surfaces, roots, or the surrounding soil (Table 4). *P. fluorescens* can also be found in an antagonistic relationship with eukaryotic microbes, including oomycetes and amoeba (35, 36, 48, 51, 59, 63–65), with the latter relationship potentially reflecting conserved mechanisms that are also used with macrophages, as has been hypothesized for other bacteria (66).

Like most members of the *Pseudomonas* genus, *P. fluorescens* species complex strains grow best in a rich, peptide-containing medium with a 0.1 to 1.0% (wt/vol) energy source (62). Examples of such basic media include nutrient broth/agar and tryptic soy broth/agar (62). Selective media that are deficient in iron allow for selective growth of *P. fluorescens*, and all but one originated from plant surfaces, roots, or the surrounding soil (Table 4). *P. fluorescens* can also be found in an antagonistic relationship with eukaryotic microbes, including oomycetes and amoeba (35, 36, 48, 51, 59, 63–65), with the latter relationship potentially reflecting conserved mechanisms that are also used with macrophages, as has been hypothesized for other bacteria (66).

Like most members of the *Pseudomonas* genus, *P. fluorescens* species complex strains grow best in a rich, peptide-containing medium with a 0.1 to 1.0% (wt/vol) energy source (62). Examples of such basic media include nutrient broth/agar and tryptic soy broth/agar (62). Selective media that are deficient in iron allow for the detection of the natural fluorescence produced by these bacteria, which is enhanced due to increased production of fluorescent siderophores. King’s A and B media (67), Pseudosel agar medium (BBL Microbiology Systems), and *Pseudomonas* agar F medium (Difco Laboratories, Detroit, MI) are all examples of pigment-enhancing media. These media also contain additional compounds, such as potassium, magnesium, and/or cetrimide, that further enable selective growth of *P. fluorescens* species complex.

### TABLE 1 Reported *P. fluorescens* infections

| Organ or tissue | No. of reported cases | Reference(s) |
|-----------------|----------------------|--------------|
| Blood           | 110                  | 8–17, 183–189|
| Bone            | 2                    | 213, 214     |
| Cerebrospinal fluid | 1             | 215          |
| Eye             | 3                    | 216–218      |
| Lung            | 3                    | 195–198      |
| Sinus           | 3                    | 219          |
| Skin/wound      | 5                    | 190, 191, 194|
| Urinary tract   | 5                    | 192–194      |
| Uterus          | 1                    | 220          |

* Total number of cases reported in the medical literature. MEDLINE searches were performed with the search term “Pseudomonas fluorescens” and filtered for human studies, with no date or language restrictions. All abstracts were read and reviewed by us, and relevant references were read in their entirety.

### TABLE 2 *P. fluorescens* isolates cultured over an 11-year period by the University of Michigan Hospital Microbiology Lab

| Parameter | % of isolates |
|-----------|---------------|
| Culture method |               |
| Cultured using routine laboratory protocols | 59.50 |
| Cultured using modified CF protocols | 40.10 |
| Sample type |               |
| Sputum samples | 53.70 |
| Throat swabs | 21.10 |
| Bronchoscopically obtained samples (BAL fluids or brushings) | 13.20 |
| Other (tracheal aspirates, sinus aspirates) | 12.00 |
| Underlying disease/cause |               |
| CF | 38.80 |
| Other chronic airway disease (COPD, asthma, non-CF bronchiectasis) | 16.10 |
| Lung transplantation | 7.40 |
| Acute pneumonia (in chronically immunosuppressed patient or hospital acquired) | 9.90 |
| Acute pneumonia (not in chronically immunosuppressed patient or hospital acquired) | 1.60 |
| Other (chronic tracheostomy, sinusitis, acute respiratory distress syndrome, bone marrow transplantation) | 26.20 |

| Cocultured bacteria | % of isolates |
|---------------------|---------------|
| “Oral flora” species | 85.10 |
| *Pseudomonas aeruginosa* | 25.60 |
| *Staphylococcus aureus* | 15.70 |
| *Stenotrophomonas maltophilia* | 11.60 |

* The data show a breakdown of 242 *P. fluorescens* isolates cultured between 1 January 2002 and 13 December 2012 (3).

* CF, cystic fibrosis; BAL, bronchoalveolar lavage.
plex bacteria. Cetrimide in particular helps to inhibit the growth of non-*Pseudomonas* microbial flora and allows for adequate pigment production from *P. aeruginosa* (68). One of the difficulties in isolation of particular species of the *Pseudomonas* genus is that they share many of the same phenotypic traits and grow under the same cultivation conditions. However, it is possible to use pigment production, which varies by species group, to visibly distinguish isolates from different groups. The blue-green pigment pyo-
Species diversity within the *P. fluorescens* species complex. Mulet et al. generated a phylogenetic tree from 107 *Pseudomonas* type strains, based on concatenated analysis of the 16S rRNA, *gyrB*, *rpoB*, and *rpoD* genes, with *Cellvibrio japonicum* Ueda107 included as the outgroup (74). The bar indicates sequence divergence. (Reproduced from reference 74 with permission of John Wiley and Sons [copyright 2010 Society for Applied Microbiology and Blackwell Publishing Ltd.]. The names of the *Pseudomonas* species that have been included in the *P. fluorescens* species complex were added to the original figure.)
 cyanin, readily produced by *P. aeruginosa* strains, is typically not produced by strains of the *P. fluorescens* species complex (62). Therefore, a mixed culture of *P. fluorescens* species complex bacteria and *P. aeruginosa* bacteria grown on cetrimide agar will produce blue fluorescent colonies of *P. aeruginosa* and nonblue fluorescent colonies of *P. fluorescens* complex bacteria.

Environmental isolates of *P. fluorescens* are readily cultivated in the laboratory by use of standard culturing techniques at a lower temperature range (5°C to 32°C), but in samples from higher temperatures or in clinical material, cultivation of *P. fluorescens* may be more difficult. *P. fluorescens* can be cultivated from environmental samples by using a simple medium with a carbon source and aerobic incubation for 24 to 48 h at 27°C to 32°C (62). However, incubation of environmental samples at temperatures of 35°C to 37°C can cause *P. fluorescens* to enter a viable-but-not-culturable (VBNC) state (69), complicating cultivation. During the VBNC state, bacteria are still metabolically active but are unable to undergo cellular division and replication (70). Bacteria in a VBNC state often will not grow when immediately transferred to standard culture conditions. *Escherichia coli*, *Listeria monocytogenes*, *Salmonella enterica* serovar Enteritidis, and *Shigella dysenteriae* are all examples of bacteria that can enter into a VBNC state (71). *Vibrio* species also undergo a switch to a VBNC state that, similar to the case of *P. fluorescens*, is prompted by a switch in temperature (72). The VBNC state is hypothesized to be a survival strategy that allows bacteria to persist in harsh environments (73). The ability of *P. fluorescens* to become VBNC could explain the phenomenon in which *P. fluorescens* can be found more frequently in human lung metagenomic DNA than is reported by standard hospital culture methods (3). However, some isolates of *P. fluorescens* from human samples have adapted well to a higher permissive temperature range than that for isolates from environmental samples. For example, we have a collection of over 30 *P. fluorescens* strains from cystic fibrosis patients that grow well at 37°C. Another study reported a series of *P. fluorescens* isolates from surface abscess, sepsisemia, and respiratory or urinary tract infections that were able to grow at 37°C (57). All seven were also able to grow at 4°C, often considered the lower limit of the optimal temperature range of *Pseudomonas* spp. (62), suggesting that these strains did not shift their temperature range but, rather, the range expanded upwards.

**GENOMICS**

**Taxonomy and Genomics of the *Pseudomonas* Genus and the *P. fluorescens* Species Complex**

Of the many species within the *Pseudomonas* genus, the *P. fluorescens* species complex contains ~20% (74). As of January 2014, the List of Prokaryotic Names with Standing in Nomenclature (LPSN) recognized 211 species and 18 subspecies in the *Pseudomonas* genus ([http://www.bacterio.net/pseudomonas.html](http://www.bacterio.net/pseudomonas.html)). This reflects a 40% increase in newly defined *Pseudomonas* species compared to the number in 2006 (74). In the last few decades, isolates classified as *P. fluorescens* have undergone extensive re-naming and reorganization, consistent with the high degree of genomic diversity within this species complex (75). Historically, any bacterium that was a Gram-negative, strictly aerobic, nonspore-forming, motile bacterium was classified as belonging to the *Pseudomonas* genus (76). The name *Pseudomonas* derives from the Greek words for “false” (*pseudes*) and “single unit” (*monas*), so it

---

**TABLE 3 Characteristics of *P. fluorescens* complex bacteria**

| Characteristic | Value |
|---------------|-------|
| Taxonomy      | Bacteria, *Proteobacteria, Gammaproteobacteria, Pseudomonadales, Pseudomonadaceae, Pseudomonas* |
| Physical characteristics | Gram-negative, rod-shaped bacilli |
|               | Motile via motile polar flagella |
|               | Non-spore-forming organisms |
|               | Produce a fluorescent pigment (pyocyanin), from which the name *P. fluorescens* is derived |
|               | Produce exopolysaccharides and readily form biofilms |
| Growth characteristics | Obligate aerobes but capable of using nitrate instead of oxygen as a final electron acceptor during cellular respiration |
|               | Optimal temperatures for growth |
|               | 25–30°C for environmental isolates |
|               | 34–37°C for mammalian isolates |
|               | Oxidase positive |
|               | Catalase positive |
|               | Grow well on Trypticase soy agar (TSA) and Luria agar (LA) |
|               | Hemolytic activity on red blood cells |
|               | No for environmental isolates |
|               | Yes for certain mammalian isolates (e.g., strain MFN1032) |
|               | Form small, white, convex colonies |
is ironic that taxonomy within the *Pseudomonas* genus is undergoing reorganization in the genomic era (77). Molecular methods, including analysis of 16S rRNA gene sequences, other highly conserved “housekeeping” genes, and, more recently, full-length genomes, have accelerated the pace of taxonomic reorganization, especially within the *P. fluorescens* species complex (76, 78–80). Multilocus sequence typing (MLST) and multilocus sequence analysis (MLSA) utilize the concept of genetic evolution at multiple conserved genes to measure evolutionary distances between species or strains (81–83). These conserved (“housekeeping”) genes are required for the basic functions of the cell and must be found in all bacteria in the comparison (84–86). Examples of housekeeping genes used in classifying *Pseudomonas* species include rpoD (σ-subunit of RNA polymerase), rpoB (β-subunit of RNA polymerase), and gyrB (β-subunit of gyrase, responsible for negative supercoiling of DNA during replication) (80, 87, 88). The combination of these three housekeeping genes and the 16S rRNA gene was used to identify members of the *Pseudomonas* genus, create a phylogenetic tree, and divide them into different groups (74, 76) (Fig. 2). One of the key findings of these analyses is that the widest range of genomic diversity in the *Pseudomonas* genus is found in the *P. fluorescens* species complex (74) (Fig. 2).

The *P. fluorescens* species complex includes at least 52 separately named species, including *P. poae, P. synxatha*, *P. tolaasi, P. brassicaearum, P. chlororaphis,* and *P. fluorescens* (23, 60, 61). The *P. fluorescens* species complex can also be divided into three smaller taxonomic clades, based on 16S rRNA gene and MLST analyses (23, 49, 74, 89, 90) (Fig. 4). Silby et al. and Loper et al. have published comparative genomic analyses of three and seven bacterial strains, respectively, within the *P. fluorescens* species complex (23, 49). One approach to studying the level of genetic diversity between *P. fluorescens* strains is via the size of the pan-genome, which is the total number of genes found across all strains. While the pan-genome of *P. aureofaciens* is 7,824 genes, the pan-genome of *P. fluorescens* bacteria is much larger, at 13,782 genes. Silby et al. noted that the shared average nucleotide and amino acid identities of the three *P. fluorescens* genomes in their study (SBW25, Pf-5, and Pf0-1) were below those of the threshold for a “species” reported by Goris et al. (90). The study by Loper et al. included the original names of the *P. fluorescens* strains in the analysis but pointed out that their phylogenetic and comparative genomic analyses support the possibility that many of these species names will change in the future.

These two studies of full-length genomes confirmed the high genetic diversity within this group of bacteria. The analysis by Loper et al. (49) included a multway BLASTp analysis to compare the seven newly sequenced *P. fluorescens* species complex genomes to previously annotated and sequenced genomes. An E value cutoff of $10^{-13}$ was selected to identify putative orthologs between the different strains (for DNA-DNA searches, E values of $<10^{-10}$ are

### TABLE 4 Summary of information on fully sequenced bacterial strains from the *P. fluorescens* species complex

| Strain         | Isolation source                          | Genome size (Mb) | % G+C   | Yr isolated/yr sequenced | GenBank accession no. | Reference(s) |
|----------------|-------------------------------------------|------------------|---------|--------------------------|------------------------|--------------|
| *P. fluorescens* strains |
| Pf0-1          | Loam soil, Sherborn, MA                   | 6.44             | 60.5    | 1988/2009                | NC_007492.2            | 23, 221      |
| SBW25          | Sugar beet phyllosphere, Oxfordshire, UK  | 6.72             | 60.5    | 1989/2009                | NC_012660              | 23           |
| A506           | Pear phyllosphere, California             | 6.02             | 59.9    | 1994/2012                | NC_017911              | 49, 222      |
| Q2-87          | Wheat rhizosphere, Washington State (same field as that for Q8r1-96) | 6.37             | 60.6    | 1987/2012                | NZ_CM001558.1         | 49, 223      |
| Q8r1-96        | Wheat rhizosphere, Washington State (same field as that for Q2-87) | 6.6              | 61      | 1996/2012                | NZ_CM001512.1         | 49, 224      |
| SS101          | Wheat rhizosphere, near city of Bergen op Zoom, The Netherlands | 6.18             | 60      | 2003/2012                | NZ_CM001513           | 49, 64       |
| WH6            | Rhizosphere of Poo sp. and *Triticum aestivum* at Hyslop Research Farm, Benton County, OR | NA               | NA      | 2008/2010 (draft)        | NA                    | 225, 226     |
| F113           | Sugar beet rhizosphere                    | 6.85             | 60.8    | 1992/2012                | NC_016830              | 50, 158      |
| R124           | Tepui orthoquartzite sandstone cave in Guiana Shield, South America | 6.3              | NA      | 2007/2013                | NZ_CM001561           | 227          |
| NCIM 11764     | Culture supplied with potassium cyanide as the sole nitrogen source | 6.97             | 59      | 1983/2012                | NA                    | 232, 233     |
| *P. protegens* strains |
| Pf-5           | Soil, Texas                               | 7.07             | 63.3    | 1978/2005                | NC_004129.6            | 228          |
| CHA0           | Tobacco roots, Morens, Switzerland        | 6.87             | 63.4    | 1983/2013                | NC_021237.1            | 229, 230     |
| *P. brassicaearum* subsp. *brassicacearum* NFM421 |
| 30-84          | Wheat rhizosphere, Kansas                 | 6.67             | 62.9    | NA/2012                  | NZ_CM001559           | 49           |
| O6             | Soil, Utah                                | 6.98             | 62.9    | 1996/2012                | NZ_CM001490           | 49, 234      |
| *P. synxatha* BG33R |
|                 | Peach rhizosphere, South Carolina         | 6.3              | 59.6    | 1993/2012                | NZ_CM001514           | 49, 235      |

*NA, not available.*
FIG 4 Phylogenetic tree of 38 Pseudomonas type strains, based on a concatenated nine-gene MLST analysis. The strains selected have full-genome sequences available through public databases. The MLST analysis was performed using nine housekeeping genes (encoding DnaE, PpsA, RecA, RpoB, GyrB, GuaA, MutL, PyrC, and AcsA), with E. coli strain K-12 used as the outgroup. A maximum likelihood tree was calculated in the online version of MAFFT (209, 210) and visualized with the software program Archaeopteryx (211). The confidence intervals after 1,000 bootstrap resamplings are indicated in red, and the branch distances are indicated in black. The bar indicates sequence divergence. P. fluorescens clade destinations are based on those proposed previously (49).
needed to provide evidence of homology and imply that the predicted homology would happen by chance only once in 10^{15} searches [91]). In the study by Silby et al. [23], a comparison of 14 _Pseudomonas_ genomes (across multiple species) was performed all-against-all, using a reciprocal FASTA approach (30% identity over 80% of the length as the minimum similarity). While there is a “core genome” of 2,789 genes within the _P. fluorescens_ species complex, only 20 are unique to the species complex itself within the _Pseudomonas_ genus, and these encode proteins involved in regulation, biofilm formation, or unknown functions (49). Within each clade of the _P. fluorescens_ species complex, the level of genetic similarity between strains is higher, with 4,188, 3,729, and 3,893 shared conserved domains between members of clades 1, 2, and 3, respectively (49).

The clade designation also offers some potential insights into functional differences between clusters of _P. fluorescens_, including the presence/absence and type of III secretion system (T3SS), a molecular “needle” complex utilized by bacteria to inject bacterial proteins into host cells (49, 92). Genes for a T3SS are found across most _Pseudomonas_ species and encode proteins involved in regulation, biofilm formation, or unknown functions (49). Within each clade of the _P. fluorescens_ species complex, the level of genetic similarity between strains is higher, with 4,188, 3,729, and 3,893 shared conserved domains between members of clades 1, 2, and 3, respectively (49).

Identifying _P. fluorescens_ in Samples by High-Throughput Sequencing

The coupling of high-throughput sequencing with the generation of 16S rRNA gene amplicon libraries from metagenomic samples has fueled the explosion in information about the microbiome and environmental microbial communities. Databases for subsequent bioinformatic analysis have continued to expand at a staggering pace. Historically, taxonomic assignment of a short read sequence from this type of analysis was limited to the family or genus level. However, as additional fully sequenced genomes become available to build phylogenetic trees of short read sequences, some genera can be resolved at the species level. This is turning out to be the case for some of the species in the _Pseudomonas_ genus: those identified by MLST and MLSA can also be identified using the V3-V5 region of the 16S rRNA gene. As illustrated in Fig. 5, a phylogenetic tree can be generated using the16S rRNA gene sequences corresponding to the V3-V5 regions of the gene and a progressive tree alignment strategy (95–98). The bootstrap values for separating _P. aeruginosa_ from the other _Pseudomonas_ species are very high. While the bootstrap values are much lower for distinguishing the non- _aeruginosa_ _Pseudomonas_ species based on the V3-V5 region alone, the short-read, high-throughput sequencing technologies that target the V3-V5 variable region of the 16S rRNA gene can offer a first-pass analysis that discriminates between members of the _P. putida_ and _P. fluorescens/_ _P. syringae_ clusters.

We have used this type of analysis, combined with other data, to demonstrate that both _P. aeruginosa_ and _P. fluorescens_ are prominent members of the respiratory microbiota of lung transplant recipients but that increases in their relative proportions are associated with widely divergent clinical associations (3). Multiple independent studies identified the presence of _P. aeruginosa_ in respiratory cultures as a positive risk factor for the subsequent development of bronchiolitis obliterans syndrome (BOS) (99–101). However, in the largest published study of lung transplant subjects to date, utilizing high-throughput sequencing for microbial identification, a negative association was reported between the presence of _Pseudomonas_ species and the diagnosis of BOS (102). In our study (3), we similarly observed high levels of _Pseudomonas_ in lung transplant recipients (as determined by high-throughput sequencing of V3-V5 16S rRNA gene amplicon libraries). However, after applying the analysis described above and adding our _Pseudomonas_ operational taxonomic units to the phylogenetic tree to delineate _P. aeruginosa_ versus _P. fluorescens_, subjects with abundant _P. aeruginosa_ had other clinical symptoms consistent with an acute infection, including positive _P. aeruginosa_ bacterial cultures. In contrast, the numerous subjects with abundant _P. fluorescens_ bacteria exhibited little evidence of acute infection, and no _Pseudomonas_ species was detected via standard clinical laboratory bacterial culture. We alluded earlier in this review to the gap in knowledge about the factors that control culturability of _P. fluorescens_ from clinical samples, which was underscored in our study. The surprising stark difference in culture positivity between these pseudomonads may explain the difference between prior culture-based studies (99–101) and the culture-independent study (102). Note that healthy controls in our study had very little signal for either _P. aeruginosa_ or _P. fluorescens_ in their bronchoalveolar lavage fluid (3). We provide this as an example of the potential power of high-throughput sequencing to provide new insights into the association of _P. fluorescens_ with humans during health and disease.

**FACTORS AFFECTING HOST COLONIZATION AND PERSISTENCE**

Antibiotics and Secondary Metabolites

_P. fluorescens_ produces a long list of secondary metabolites that allow it to successfully vie with competing microorganisms. Examples include phenazine (26–28), hydrogen cyanide (HCN) (29), 2,4-diacylhexanoylglutaric acid (DAPG) (30, 31), rhizoxin (32–34), and pyoluteorin (35, 36). Phenazines can be produced by Gram-negative bacteria found in soil and marine environments, with _Pseudomonas_ spp. being one of the major producers (28). Phenazines are pigmented compounds that have antitumor, anti-malarial, antiparasitic, and antimicrobial activities (26). _P. fluorescens_ produces the yellow phenazine phenazine-1-carboxylic acid (PCA) (28). Hydrogen cyanide is a volatile, colorless compound that inhibits cytochrome _c_ oxidases and other metalloproteins in competing bacteria (33). The production of HCN by rhizosphere-inhabiting _P. fluorescens_ suppresses plant disease (29). While it has not been studied for _P. fluorescens_, other _Pseudomonas_ spp. are capable of producing HCN during human disease, such as cystic fibrosis (103). The anaerobic regulator protein ANR regulates the _hcnABC_ gene cluster, which encodes hydrogen cyanide synthase, and, due to the oxygen sensitivity of the synthase, ensures that the genes are expressed only under low-oxygen conditions (104). DAPG production plays a significant role in the plant disease control activity of many _P. fluorescens_ strains (30). Despite its importance, the DAPG biosynthetic cluster (phi) has been lost from all
Phylogenetic tree of 38 Pseudomonas type strains, based on the V3-V5 region sequence of the 16S rRNA gene (V3 primer, positions 442 to 492; and V5 primer, positions 822 to 879 [numbered according to the E. coli 16S rRNA gene map]). The strains selected have full-genome sequences available through public databases. The V3-V5 sequence primers (212) were aligned to each genome by using DNAstar SeqBuilder software. A maximum likelihood tree was calculated in the online version of MAFFT (209, 210) and visualized with the software program Archaeopteryx (211). The confidence intervals after 1,000 bootstrap resamplings are indicated in red, and the branch distances are indicated in black. The bar indicates sequence divergence.
but a subset of *P. fluorescens* strains through evolution (31). Members of clades 1 and 2 of the *P. fluorescens* species complex (such as *P. protegens* Pf-5, *P. fluorescens* Q8r1-96, and *P. fluorescens* Q2-87) have retained the DAPG biosynthesis cluster, while all members of clade 3 do not possess this cluster (49). Intragenomic recombination and rearrangement occur frequently at this locus, such that DAPG-producing strains often have multiple versions of the *phl* gene cluster. In the phylogenetic lineage that retains DAPG synthesis, the gene cluster has maintained its structure, even though it has been relocated multiple times in the various *P. fluorescens* genomes (31). Rhizoxins are 16-membered macrocyclic lactones that interfere with microtubulin dynamics during mitosis by binding to β-tubulin (32) and that show inhibitory activity against fungi, bacteria, and tumors (33, 34). The rhizoxin-producing gene cluster in *P. fluorescens* is shared with another gammaproteobacterial genus, *Burkholderia* (105). Pyluteorin was first isolated from a *P. aeruginosa* strain (106) but is now known to be produced by multiple *Pseudomonas* spp., including *P. fluorescens* (35). It has been studied in *P. fluorescens* strains Pf-5 and CHA0 for its antibacterial activity and ability to improve plant health (35, 36). While the activities of these secondary metabolites on human hosts remain to be determined, they benefit the survival of *P. fluorescens* in polymicrobial environments, opening the possibility of a role for these metabolites in survival of *P. fluorescens* in the human microbiome.

Other secondary metabolites produced by *P. fluorescens*, notably pyrrolnitrin and the pseudomonic acids, have been formulated for medical and agricultural uses. Pyrrolnitrin, a chlorinated molecule with antifungal activity, was developed into both a topical antibiotic (40, 41, 109, 110). Topical mupirocin (2% concentration), blue pigment, is produced by *P. fluorescens* and is the major pseudomonic acid (90%) in mupirocin, a topical antibiotic with antifungal activity, was developed into both a topical antibiotic (40, 41, 109, 110). Topical mupirocin (2% concentration) is effective for treatment of superficial skin infections, such as impetigo, caused by the Gram-positive bacteria *S. aureus* and *S. epidermidis* (35) and is the major pseudomonic acid (90%) in mupirocin, a topical antibiotic (40, 41, 109, 110). Topical mupirocin (2% concentration) is effective for treatment of superficial skin infections, such as impetigo, caused by the Gram-positive bacteria *S. aureus* and *S. epidermidis* (35). Mupirocin is effective for treatment up of 106 CFU/g, were identified on the “blue” cheese samples (121). Beyond being blue, little is known about this particular pigment produced by *P. fluorescens*. Pyocyanin, another blue pigment, is produced by *P. aeruginosa*, but this secondary metabolite has not yet been identified in *P. fluorescens* (122). This incident indicated either the emergence of a new strain of *P. fluorescens* that had acquired the biosynthesis machinery for a new blue pigment or horizontal acquisition of the biosynthesis machinery from another, closely related *Pseudomonas* strain.

**Two-Component Gene Systems**

*P. fluorescens* also contains a two-component GacS-GacA system that plays a role in environmental sensing. This system controls the expression of multiple secondary metabolites and enzymes in *P. fluorescens*, including DAPG, pyoluteorin, HCN, phospholipase C, and exoprotease (123–126). In *P. aeruginosa*, GacA controls gene expression through acylated homoserine lactone (AHL) signaling (127, 128). However, GacA can also function independently of AHL signaling (127), and this AHL-independent GacA cascade has been reported for *P. fluorescens* strain CHA0 (129). The diffusible non-AHL bacterial signal, whose chemical nature is still under investigation, turns on and regulates a two-component GacS-GacA system that activates the transcription of a novel small, noncoding RNA, RsmA (129). RsmA then combines with a riboregulator (RsmY), which is a small, untranslated RNA that can regulate cellular processes (130–133), to positively regulate the expression of downstream genes at a posttranscriptional level (65).
Quorum Sensing and Biofilms

Bacteria are able to regulate their population density through the release and sensing of signal molecules, i.e., quorum sensing (134, 135). Quorum sensing involves regulation of genes that control motility (swimming and swarming), antibiotic synthesis, and biofilm formation. Genes involved in biofilm formation and quorum sensing are found in the core genome of the *P. fluorescens* species complex (49). Quorum sensing and biofilm formation are integral to the many environmental niches occupied by *P. fluorescens* and allow it to colonize surfaces such as hospital equipment and food-grade stainless steel surfaces (52, 136), as well as the surfaces of plants, showerheads, and even indoor wall surfaces (23, 24, 137). *P. fluorescens* readily forms biofilms with highly complex, three-dimensional (3-D) structures (Fig. 6) (20, 52–56), and strains that form plant-associated biofilms are often important biocontrol agents that protect plants against pathogenic fungi (54, 138). Less is known about *P. fluorescens* biofilm formation on mammalian surfaces, though the adaptability to a 37°C permissive growth range is linked to biofilm formation on human cells (53). Thus, whether on plants or human cells, biofilm formation is likely important for successful long-term colonization by *P. fluorescens*.

Two types of quorum sensing systems have been described for *P. fluorescens*: the AHL/lux and hdtS systems. In Gram-negative bacteria, AHL molecules are produced by LuxI-like proteins and interact with LuxR-like proteins to form dual AHL–LuxR complexes. This AHL–LuxR complex then binds lux boxes of quorum sensing-regulated genes in order to either turn on or off/down their expression (139). A luxI–luxR-like system in *P. fluorescens* was first discovered in the strain NCIMB 10586 and was termed the *mpul–mpur* system due to its regulation of the antimicrobial mupirocin biosynthesis pathway (140). Another quorum sensing system, the hdtS system, was later discovered in *P. fluorescens* strain F113 (141). The hdtS gene encodes a novel AHL synthase that produces separate signaling molecules: an N-(3-hydroxy-7-tetradecenoyl)homoserine lactone (3-OH-C14:1-AHL), an N-decanoylhomoserine lactone (C10-AHL), and a C9-AHL. Though the signaling molecules and synthase have been elucidated, the genes regulated by the hdtS system are still unknown, and no detectable phenotype in F113 has yet been linked to the signaling molecules (141).

The second messenger cyclic di-GMP (c-di-GMP) is essential for regulation of steps involved in biofilm formation, including the production of LapA, an adhesive protein necessary for *P. fluorescens* attachment to surfaces (142). LapA is negatively regulated by the periplasmic protease LapG and positively regulated by the inner membrane protein LapD (143). LapG typically cleaves LapA from the bacterial surface, but when LapD is bound by c-di-GMP, LapD undergoes a conformation change that allows it to bind to LapG, inhibiting LapA cleavage. Diguanylate cyclases catalyze c-di-GMP synthase activity, and in *P. fluorescens* Pf0-1, there are a total of 43 potential diguanylate cyclases encoded in the genome, each potentially connected to a different aspect of biofilm formation (144).

Type III Secretion Systems

Type III secretion systems (T3SSs) are molecular needle-like complexes that act like syringes to deliver bacterial proteins, called effectors, from the bacterial cytoplasm directly into host cells (92) (Fig. 7). T3SSs are highly conserved genomic clusters typically found in bacteria that have close interactions with eukaryotic hosts (often transferred horizontally between phylogenetically unrelated bacteria), and the type of T3SS usually mirrors the type of interaction a bacterium has with the eukaryotes in its environment. The first T3SS was described for *Yersinia*, which delivers Yop (*Yersinia* outer protein) effector proteins into human host cells (145, 146). A total of five different T3SS groups have since been described: the Ysc group (which includes the *Yersinia* Ysc, *P. aeruginosa* Psc, Bordetella Bsc, Rhizobium Rsc, and *Chlamydia* sp. T3SSs), the Hrp1 group (found in non-*aeruginosa* *Pseudomonas* spp. and *Erwinia* spp.), the Hrp2 group (found in *Xanthomonas* spp. and *Ralstonia* spp.), the Inv/Mxi/Spa group (which includes the *Salmonella* SPI-I, *Shigella* sp., and *Yersinia enterocolitica* Ysa T3SSs and T3SS2 of enterohemorrhagic *E. coli* [HEEC]), and the Esa/Ssa group (including the *Salmonella* SPI-2 and enteropathogenic *E. coli* [EPEC] T3SSs and EHEC T3SS1) (147).

The Hrp1 family is the most common T3SS found among *P. fluorescens* strains (46–50). The Hrp (hypersensitivity response and pathogenicity) system triggers the hypersensitivity defense response in resistant plants, while leading to disease in susceptible plants, and was first described for *P. syringae* (148). Like the T3SS found in *Yersinia*, the Hrp1 system is involved in delivering bacterial proteins directly into host cells (149–152) (Fig. 7). While the fully sequenced *P. fluorescens* strains SBW25, BG33R, A506, SS101, Q8r1-96, and Q2-87 have at least one copy of the Hrp1 family T3SS, Pf0-1 and Pf-5 do not carry the gene cluster at all (49, 153). The activity and functionality of the Hrp1 system have been worked out for only a couple of the strains in which it has been found. The Hrp1 T3SS of *P. fluorescens* Pf29Arp, a strain known for its ability to reduce the severity of wheat take-all, shows activity during the colonization of wheat rhizospheres (46). The homologous Hrp1 T3SS in strain SBW25 is induced during sugar beet rhizosphere colonization (154) and can induce a hypersensitive response in tobacco (47, 155). Interestingly, in addition to Hrp1 system effectors, SBW25 also contains the T3SS effector ExoY (156), which in *P. aeruginosa* targets the actin cytoskeleton of eukaryotic cells (157). Since most of the work on the functionality of the Hrp1 T3SS in *P. fluorescens* has been done *in vitro*, many of the target host cells are still unknown, but the presence of the ExoY effector protein in some strains suggests that there might be an additional, nonplant use of this T3SS in SBW25 and genetically related strains.

Additional evidence that *P. fluorescens* strains may target their T3SSs against eukaryotic cells was provided in 2013, when a SPI-1-like T3SS gene cluster was discovered in strain F113 (51) (Fig. 7). The F113 strain was originally isolated from sugar beet rhizosphere (158) and can inhibit the growth of plant-pathogenic *E. coli* (159). The activity and functionality of the Hrp1 T3SS in *P. fluorescens* has been done *in vitro*, many of the target host cells are still unknown, but the presence of the ExoY effector protein in some strains suggests that there might be an additional, nonplant use of this T3SS in SBW25 and genetically related strains.

Additional evidence that *P. fluorescens* strains may target their T3SSs against eukaryotic cells was provided in 2013, when a SPI-1-like T3SS gene cluster was discovered in strain F113 (51) (Fig. 7). The F113 strain was originally isolated from sugar beet rhizosphere colonization (154) and can induce a hypersensitive response in tobacco (47, 155). Interestingly, in addition to Hrp1 system effectors, SBW25 also contains the T3SS effector ExoY (156), which in *P. aeruginosa* targets the actin cytoskeleton of eukaryotic cells (157). Since most of the work on the functionality of the Hrp1 T3SS in *P. fluorescens* has been done *in vitro*, many of the target host cells are still unknown, but the presence of the ExoY effector protein in some strains suggests that there might be an additional, nonplant use of this T3SS in SBW25 and genetically related strains.

The activity and functionality of the Hrp1 system have been worked out for only a couple of the strains in which it has been found. The Hrp1 T3SS of *P. fluorescens* Pf29Arp, a strain known for its ability to reduce the severity of wheat take-all, shows activity during the colonization of wheat rhizospheres (46). The homologous Hrp1 T3SS in strain SBW25 is induced during sugar beet rhizosphere colonization (154) and can induce a hypersensitive response in tobacco (47, 155). Interestingly, in addition to Hrp1 system effectors, SBW25 also contains the T3SS effector ExoY (156), which in *P. aeruginosa* targets the actin cytoskeleton of eukaryotic cells (157). Since most of the work on the functionality of the Hrp1 T3SS in *P. fluorescens* has been done *in vitro*, many of the target host cells are still unknown, but the presence of the ExoY effector protein in some strains suggests that there might be an additional, nonplant use of this T3SS in SBW25 and genetically related strains.

Additional evidence that *P. fluorescens* strains may target their T3SSs against eukaryotic cells was provided in 2013, when a SPI-1-like T3SS gene cluster was discovered in strain F113 (51) (Fig. 7). The F113 strain was originally isolated from sugar beet rhizosphere (158) and can inhibit the growth of plant-pathogenic bacteria, oomycetes, fungi, and a wide range of nematodes (159–161). Predation against protozoa in both terrestrial and aquatic environments is an important factor influencing bacterial community makeup and behavior (37, 38, 162). In F113, the SPI-1 T3SS *hilA* promoter shows increased expression during close contact with the amoeba *Acanthamoeba castellanii*, suggesting that this T3SS is directly involved in protecting the bacterium from amoeba predation. Interestingly, both the Hrp1 and SPI-1 systems in F113 appear to be involved in protection against predation by the worm *Caenorhabditis elegans* (51). A similar result was found with the Hrp1 system of *P. fluorescens* CHA0 (163). Additional SPI-T T3SSs have also been found in *P. fluorescens* strains HK44 (164) and Q2-87 (49), providing further evidence of T3SS action.
FIG 6 Scanning electron micrographs of *P. fluorescens* biofilms. For these photomicrographs, Baum et al. prepared and cryopreserved 14-day biofilms from *P. fluorescens EvS4-B1* monocultures (56). (A) Fibrillary structures made up of twisted fibers (arrow). Bar = 1 μm. (B) Flat sheets of material (arrowheads), with some of the sheets wrapped around other structures (arrow). Bar = 20 μm. (C) The inside core of the “wrapped” structures, consisting of bacteria (B) embedded in an extracellular matrix of particulate matter, and a thin sheet of material (arrow). Bar = 1 μm. (D) The outer sheet (arrowheads), which envelops an inner core consisting of fibers forming irregular network-like structures (arrows). Bar = 10 μm. (E) Network consisting of fibers arranged in a periodic pattern, with bacteria (arrows) dispersed throughout the network. Bar = 2 μm. (F) A sheet of material (S), consisting of extracellular material and dead cells, covering and attaching to the fiber network and including associated bacteria (B) and particulate matter (P). Bar = 2 μm. (Reprinted from BMC Microbiology [56] under a Creative Commons license [http://creativecommons.org/licenses/by/2.0/].)
outside the plant ecosphere. Thus, the identification of multiple T3SSs across the \textit{P. fluorescens} species complex that target plant and nonplant eukaryotic cells supports the model of a wider interaction of \textit{P. fluorescens} with eukaryotic hosts.

**INTERACTION OF \textit{P. FLUORESCENS} WITH HUMAN CELLS**

Environmental isolates of \textit{P. fluorescens} have an optimal temperature growth range of 25 to 30°C and are not virulent to human cells, but certain strains of \textit{P. fluorescens} isolated from clinical samples have a higher permissive growth range, up to 37°C, and show increased virulence against human cells \cite{53,57,59}. Two \textit{P. fluorescens} strains, MFY162 and MFN1032, can adhere to human glial cells in culture, and MFN1032 can induce apoptosis. Originally isolated from an individual with a lung infection \cite{57}, MFN1032 not only exhibits cytotoxicity on human intestinal epithelial cells \textit{in vitro} but also triggers a proinflammatory response \cite{165}. Human airway epithelial cells exposed to a different strain of \textit{P. fluorescens} have been shown to trigger both antiapoptotic responses,
via the epidermal growth factor receptor (EGFR), and interleukin-8 (IL-8) production, via Toll-like receptor 4 (TLR4)-independent NF-kB signaling pathways (166). Exposure to a strain of *P. fluorescens* isolated from a moldy building decreased viability of mouse macrophages (RAW cells) while inducing production of nitric oxide, tumor necrosis factor (TNF), and IL-6 (167).

On red blood cells, *P. fluorescens* MFN1032 displays both cell-associated and secretion-dependent hemolytic activity. The secretion-dependent pathway is positively regulated by the GacS-GacA two-component system (58), the same two-component system that regulates phase variation in this strain (168). This hemolytic activity involves the production of phospholipase C and biosurfactants, similar to that seen for pathogenic *P. aeruginosa* (169). Similalrities between *P. aeruginosa* and *P. fluorescens* also exist within the functionality of the cell-associated hemolytic activity of MFN1032. The cell-associated hemolytic activity is independent of the secretion-association hemolytic activity, is active at 37°C, occurs without the secretion of phospholipase C and biosurfactants, and does not depend on the GacS-GacA two-component system (170). In *P. aeruginosa*, cell-associated hemolytic activity occurs alongside type III secretion of the PcrV, PopB, and PopD effectors (171). MFN1032 also harbors the genes necessary to produce a T3SS (170), the hrcRST gene cluster, which shares a high level of homology to the hrcRST genes of the hrcU operon in *P. syringae* DC3000. When this operon is mutated, MFN1032 is no longer able to produce cell-associated hemolytic activity (170). In *P. aeruginosa*, similar mutations in the T3SS also abolish its cell-associated hemolytic activity. Thus, adaptation of *P. fluorescens* MFN1032 results in an increased temperature permissivity along with hemolytic activity against human cells that is similar to that found in *P. aeruginosa*.

The production of cyclolipopeptides (CLPs) by *P. fluorescens* MFN1032 is another functional characteristic that is altered during a shift to higher temperatures. Cyclolipopeptides are the most widely studied biosurfactants produced by *P. fluorescens* and are involved in swarming motility, biofilm formation, and colonization of host surfaces (172). If MFN1032 is grown for multiple generations at 37°C, CLP functionality is lost, with ~4 × 10^{-3} CLP-deficient mutants found per generation (58). High mutation rates, inversions of DNA segments, DNA methylation, and epigenetic switches are all mechanisms that bacteria use to alter their genomes in the process of adaptation, which allows survival in changing environments and an increase in overall fitness with time (173). In the case of the *P. aeruginosa* T3SS, there is an epigenetic switch between a noninducible and an inducible state (168). Using a Boolean modeling system, a similar epigenetic switch has been shown to be the likely mechanism by which *P. fluorescens* regulates its CLP production (168). In much the same way that chronic *P. aeruginosa* strains lose the ability to produce biofilms after long-term growth in a cystic fibrosis lung (174), *P. fluorescens* also has a mechanism to turn off energy-expensive surfactant production after long-term growth at physiologically relevant temperatures.

**CLINICAL SIGNIFICANCE**

**P. fluorescens** as a Disease-Causing Agent

The bloodstream is by far the most common site reported for *P. fluorescens* infection (opportunistic) in humans. Most reported cases have been iatrogenic, with bacteremia attributable to either transfusion of contaminated blood products (7–12) or use of contaminated equipment associated with intravenous infusions (13–17). *P. fluorescens* bacteremia has occurred in outbreaks (8, 13–16), with the largest affecting at least 80 patients in 6 states after indirect exposure to contaminated heparinized saline flushes prepared at a common compounding pharmacy (16). Of these patients, 41% were bacteremic more than 84 days after exposure; all of these delayed-onset patients had indwelling ports for venous access, indicating that *P. fluorescens* can persist endovascularly when an indwelling catheter is in place. The abilities to grow at refrigerated temperatures and to form biofilms on fomite surfaces make *P. fluorescens* contamination a particular problem for blood infusion-related infections and outbreaks.

Confounding the diagnosis of *P. fluorescens* bacteremia is the well-described phenomenon of “pseudobacteremia” due to environmental contamination of blood culture collection bottles and equipment by the organism (175–182). Indeed, in a systematic review of the medical literature, more positive *P. fluorescens* blood culture results were attributable to pseudobacteremia (175–182) than to true bacteremia (8–17, 183–189). Sources have included blood culture bottles cleaned with contaminated disinfectant (179) and, most commonly, contaminated blood collection tubes used prior to culture bottle inoculation (176, 178, 180–182). Despite not reflecting “true” human pathology, pseudobacteremia is a legitimate clinical problem, resulting in diagnostic confusion for clinicians and inappropriate antibiotic exposure for patients (181). The diagnosis of pseudobacteremia should be considered when patient symptoms are discordant with disseminated bacterial infection and bacteria that are uncommon infectious agents (such as *P. fluorescens*) are isolated, especially in a geographic or temporal cluster.

Identification of *P. fluorescens* as an acute cause of infection (opportunistic or primary) in sites other than the blood has been rare and sporadic (Table 1). Two reports have identified *P. fluorescens* in skin wounds and abscesses following dog bites (190, 191), and in one instance, the patient subsequently developed disseminated *P. fluorescens* bacteremia (191). *P. fluorescens* has been implicated as a cause of acute bacterial cystitis (192–194), both with (192) and without (193) the presence of an indwelling urinary catheter. In a study comparing the oral microbiomes of 20 solid organ transplant recipients and 19 nonimmunosuppressed control subjects, *P. fluorescens* was abundant in the saliva of nearly 50% of transplant subjects while being nearly absent from nontransplant controls (1). In another study of 258 stomach wall biopsies collected from ulcerative intestinal disorders, 93% had evidence of the presence of *P. fluorescens* (identified via both culture-dependent and -independent methods) (2). Thus, *P. fluorescens* can clearly establish itself in diseased humans, but questions remain about the pathogenicity of such interactions and whether the involved strains are all restricted to a specific clade.

**P. fluorescens** in Respiratory Diseases

While *P. fluorescens* has repeatedly been cultured from respiratory specimens, its role in pneumonia or other respiratory infections is unclear. *P. fluorescens* has been cultured from the tracheal aspirates of patients receiving mechanical ventilation and subsequently identified as an organism in the humidifier water used in the ventilator circuit (195), but it is unclear if the tracheal aspirate culture results reflected acute infection or benign colonization. In
another case study, during recovery from a recent polymicrobial peritonitis, a patient developed clinical evidence of pneumonia, with sputum cultures that were positive for \textit{P. fluorescens} (196). The patient improved after treatment with a third-generation cephalosporin, and subsequent sputum cultures did not grow \textit{P. fluorescens}. In another report, \textit{P. fluorescens} is mentioned in the etiology of community-acquired pneumonia in a single patient, but clinical details are lacking (197). Using amplification of bacterial 16S rRNA genes, another study detected \textit{P. fluorescens} and other bacteria in the bronchoalveolar lavage fluid acquired from a single patient with clinically diagnosed ventilator-associated pneumonia (198). Most notably, in a survey of over 1,000 respiratory cultures acquired from subjects with cystic fibrosis, Klinger and Thomassen identified the organism in roughly 2% of specimens (199) and considered the organism a colonizer rather than an acute pathogen. We have reported, using bronchoalveolar lavage fluid acquired from lung transplant recipients, that \textit{P. fluorescens} is frequently identified in this patient population, in the absence of evidence of acute infection (3).

In a survey of bacterial culture isolates at the University of Michigan Hospital, \textit{P. fluorescens} was cultured from respiratory specimens with relative frequency (3) (Table 2). Over an 11-year period, \textit{P. fluorescens} was cultured from over 240 distinct respiratory specimens, or roughly 2 specimens per month. Among patients with positive \textit{P. fluorescens} respiratory cultures, the most common underlying pulmonary condition was cystic fibrosis (38.8% of all isolates), followed by other chronic airway diseases (chronic obstructive pulmonary disease [COPD], asthma, and non-cystic-fibrosis bronchiectasis [16.1%]). \textit{P. fluorescens} was often coisolated with other organisms, most often (85.1%) species designated "oral flora" by the clinical microbiology laboratory, followed by \textit{P. aeruginosa} (25.6%), \textit{Staphylococcus aureus} (15.7%), and \textit{Stenotrophomonas maltophilia} (11.6%). In no cases was \textit{P. fluorescens} the unambiguous causative agent in a monomicrobial pneumonia. This survey highlights the fact that \textit{P. fluorescens} directly contributes to these chronic inflammatory conditions or whether anti-I2 antibodies are only indirect biomarkers of disease is undetermined.

\textbf{FUTURE PERSPECTIVES}

Despite being identified in the last half of the 1800s and more recent associations with human disease, the role of \textit{P. fluorescens} species complex in human health and disease remains largely unexplored. Research in the last 2 decades on the genetic, molecular, environmental, and immunological aspects of the \textit{P. fluorescens} species complex has begun to expand our understanding of these bacteria overall and to lay the groundwork for investigating their role in human health. Full-genome sequencing and comparison led to the discovery of potential pathogenic traits (such as T3SSs and T-cell superantigens) and further revealed the high level of genetic diversity within the \textit{P. fluorescens} species complex. The discovery of human-adapted \textit{P. fluorescens} strains with higher permissive temperature ranges revealed that these bacteria can readily exist outside plant and soil niches, and even potentially change their functional phenotypes in response to a new, mammal-based niche. Clinical surveys have also found that \textit{P. fluorescens} is regularly cultured from clinical samples even in the absence of acute infection or outbreak. Studies are beginning to identify \textit{P. fluorescens} via high-throughput sequencing in multiple sites of the human body, suggesting that the human-\textit{P. fluorescens} connection will only grow as more studies are reported.

However, there is still much more that is unknown about the role of the \textit{P. fluorescens} species complex in human disease. Taxonomic classifications within the \textit{P. fluorescens} species complex are still in flux; a general consensus on what constitutes a \textit{P. fluorescens} strain would codify classification and greatly assist in functional microbiology research, as well as the clinical microbiology lab and clinician. Almost nothing is known about the host response to \textit{P. fluorescens}, and while correlations have been found between \textit{P. fluorescens}-specific antibodies and Crohn’s disease, the mechanisms underlying this connection have not been identified. Finally, there is a glaring disparity between reports in the medical literature that only find \textit{P. fluorescens} infections during outbreaks/extreme situations and clinical surveys that readily identify \textit{P. fluorescens} in human samples in the absence of acute disease. The former suggest that \textit{P. fluorescens} is accidently associated with human hosts through contamination or when the host is immunocompromised; the latter suggest that there are strains of \textit{P. fluorescens} that can colonize and thrive in a human host. Additional work on the genomics, molecular microbiology, and host immune response to the \textit{P. fluorescens} species complex will provide insight into the roles these bacteria play in human health and disease.
ACKNOWLEDGMENTS

The following funding sources have provided research support for the authors: The National Institute of Allergy and Infectious Diseases (B.S.S. [grant T32AI070528]), The National Heart, Lung and Blood Institute (G.B.H. [grants U01HL098861 and R01HL114447] and R.P.D. [grant T32HL00774921]), The Cystic Fibrosis Foundation (J.L.L.), and The Nestibb Program for Cystic Fibrosis Research (J.L.L. and G.B.H.).

We thank the following individuals for their contributions to the manuscript: Karin J. Ekholm for translation of the Baader 1887 reference, Ellen Hunter for her assistance with the photographs of the Gram stains, and Patrick Lane for his assistance with the graphics.

REFERENCES

1. Diaz PI, Hong BY, Frias-Lopez J, Dupuy AK, Angeloni M, Abusleme L, Terzi E, Ioannidou E, Straubaus LG, Dongari-Bagtzoglou A. 2013. Transplantation-associated long-term immunosuppression promotes oral colonization by potentially opportunistic pathogens without impacting other members of the salivary bacteriome. Clin. Vaccine Immunol. 20:892–897. http://dx.doi.org/10.1128/CTV.00754-12.

2. Patel SK, Pratap CB, Verma AK, Jain AK, Dixit VK, Nath G. 2013. Pseudomonas fluorescens—like bacteria from the stomach: a microbiological and molecular study. World J. Gastroenterol. 19:1056–1067. http://dx.doi.org/10.3748/wjg.v19.i7.1056.

3. Dickson RP, Erb-Downward JR, Freeman CM, Walker N, Scales BS, Beol ME, Martzner FJ, Curtis JL, Lama VN, Huffnagle GB. 2014. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. PLoS One 9:e97214. http://dx.doi.org/10.1371/journal.pone.0097214.

4. Stenhousen MA, Milner LV. 1992. A survey of cold-growing gram-negative organisms isolated from the skin of prospective blood donors. Transfus. Med. 2:223–237. http://dx.doi.org/10.1111/j.1365-3148.1992.tb01611.x.

5. Wagner J, Short K, Catto-Smith AG, Cameron DJ, Bishop RF, Kirkwood CD. 2008. Identification and characterisation of Pseudomonas 16S ribosomal DNA from ileal biopsies of children with Crohn’s disease. PLoS One 3:e3578. http://dx.doi.org/10.1371/journal.pone.0003578.

6. Baader A, Garre C. 1887. Über Antagonisten unter den Bakterien. Correspondenzbl. Schweiz. Ärzte: 13:385–392.

7. Gibaud M, Martin-Dupont P, Dominguez M, Laurentjoye P, Chassaing B, Leng B. 1984. Pseudomonas fluorescens septicaemia following transfusion of contaminated blood. Presse Med. 13:2583–2584.

8. Hsueh PR, Teng LJ, Hsu WC, Sun CC, Ho SW, Luh KT. 1998. Outbreak of Pseudomonas fluorescens bacteremia among oncology patients. J. Clin. Microbiol. 36:2914–2917.

9. Khabbaz RF, Arnow PM, Highsmith AK, Herwaldt LA, Chou T, Jarvis WR, Lerner GM, Jensen B, Pascoe N, Saiman L, McHale J, Wilkins M, Schoonover FA, Jr, Wilson B, Lee M, Brokopp C. 1978. Nosocomial meningitis and bacteremia due to contaminated amphotericin B. JAMA 239:416–418.

10. Landers CJ, Cohary O, Misra R, Yang H, Lin YC, Braun J, Targan SR. 2002. Selected loss of tolerance evidenced by Crohn’s disease-associated immune responses to auto- and microbial antigens. Gastroenterology 123:689–699. http://dx.doi.org/10.1053/gast.2002.35579.

11. Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. 2004. Sero-reactivity to microbial components in Crohn’s disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99:2367–2384. http://dx.doi.org/10.1111/j.1574-6941.2004.04017.x.

12. Ilhanen S, Tervo L, Hallitunen T, Wei B, Braun J, Rantala I, Honkanen T, Kronenberg M, Cheroute H, Turovskaya O, Autio V, Ashorn M. 2006. Elevated serum anti-12 and anti-OmpW antibody levels in children with IBD. Inflamm. Bowel Dis. 12:389–394. http://dx.doi.org/10.1097/MIB.0b013e31836df472.

13. Iwanen S, Tervo L, Hallitunen T, Wei B, Braun J, Rantala I, Honkanen T, Kronenberg M, Cheroute H, Turovskaya O, Autio V, Ashorn M. 2006. Elevated serum anti-OmpW antibody levels in children with IBD. Inflamm. Bowel Dis. 12:389–394. http://dx.doi.org/10.1097/MIB.0b013e31836df472.

14. Papadakis KA, Ippoliti A, Targan SR, Fleshner PR. 2006. Antibodies to 12 predict clinical response to fecal diversion in Crohn’s Disease. Inflamm. Bowel Dis. 12:1122–1130. http://dx.doi.org/10.1097/MIB.0b013e3180253833.

15. Silby MW, Cerdeno-Tarraga AM, Vernikos GS, Giddens SR, Jackson RW, Preston GM, Zhang XX, Moon CD, Gehrig SM, Godfrey SA, Knight CG, Malone JG, Robinson Z, Spiers AJ, Harris S, Challis GL, Yap ax AM, Harris D, Seeger K, Murphy L, Rutter S, Squares R, Quail MA, Saunders E, Mavromaki C, Klett BS, Bentley SD, Hotha S, Stephens E, Thomas CM, Parkhill J, Levy SB, Rainey PB, Thomson NR. 2009. Genomic and genetic analyses of diversity and plant interactions of Pseudomonas fluorescens. Genome Biol. 10:R51. http://dx.doi.org/10.1186/gb-2009-10-5-51.

16. Feazel LM, Baumgartner LR, Peterson KL, Frank DN, Harris JK, Pace NR. 2009. Opportunistic pathogens enriched in showerhead biofilms. Proc. Natl. Acad. Sci. U. S. A. 106:16639–16639. http://dx.doi.org/10.1073/pnas.0908446106.

17. Haas D, Defago G. 2005. Biological control of soil-borne pathogens by fluorescent pseudomonads. Nat. Rev. Microbiol. 3:307–319. http://dx.doi.org/10.1038/nrmicro1129.

18. Laursen JB, Nielsen J. 2004. Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. Chem. Rev. 104:1663–1688. http://dx.doi.org/10.1021/cr020473j.

19. Weller DM, Landa BB, Mavrodi OV, Schroeder KL, De La Fuente L, Blouin Bankhead S, Allende Molar R, Bonsall RF, Mavrodi DV, Thomashow LS. 2007. Role of 2,4-diacetylphloroglucinol-producing fluorescent Pseudomonas spp. in the defense of plant roots. Plant Biol. (Stuttg.) 9:4–20. http://dx.doi.org/10.1055/s-2006-924473.

20. Mavrodi DV, Blankenfeldt W, Thomashow LS. 2006. Phenazine compounds in fluorescent Pseudomonas spp. biosynthesis and regulation. Annu. Rev. Phytopathol. 44:417–445. http://dx.doi.org/10.1146/annurev.phyto.44.031006.145710.

21. Ramette A, Moenne-Loccoz Y, Defago G. 2003. Prevalence of fluorescent pseudomonads producing antifungal phloroglucinols and/or hydrogen cyanide in soils naturally suppressive or conducive to tobacco black root rot. FEMS Microbiol. Ecol. 44:35–43. http://dx.doi.org/10.1016/S0168-6496(02)00188-7.

22. Keel C, Weller DM, Natsch A, Defago G, Cook RJ, Thomashow LS. 1996. Conservation of the 2,4-diacetylphloroglucinol biosynthesis locus among fluorescent Pseudomonas strains from diverse geographic locations. Appl. Environ. Microbiol. 62:552–563.

23. Moynihan JA, Morrissey JP, Coppoose ER, Stiekema WJ, O’Gara F, Boyd EF. 2009. Evolutionary history of the phi gene cluster in the plant-
associated bacterium Pseudomonas fluorescens. Appl. Environ. Microbiol. 75:2122–2131. http://dx.doi.org/10.1128/AEM.00252-08.

32. Takahashi M, Matsumoto S, Iwasaki S, Yahara I. 1990. Molecular basis for determining the sensitivity of eucaryotes to the antibiotic drug rhizoxin. Mol. Gen. Genet. 222:169–175. http://dx.doi.org/10.1007/BF00638141.

33. Graham H, Lopreti P. 2009. Genetics of secondary metabolite production by Pseudomonas spp. Nat. Prod. Rep. 26:1408–1446. http://dx.doi.org/10.1039/b917075b.

34. Tsurow T, Oh-hara, Iida TH, Tsukagoshi S, Sato Z, Matsuda I, Iwasaki S, Okuda S, Shimizu F, Sasagawa K, Fukami M, Fukuda K, Arakawa M. 1986. Rhizoxin, a macrolyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res. 46:381–385.

35. Schneider U, Keel C, Blumer C, Troxler J, Defago G, Haas D. 1995. Amplification of the housekeeping sigma factor in Pseudomonas fluorescens CHA0 enhances antibiotic production and improves biocontrol abilities. J. Bacteriol. 177:5387–5392.

36. Sarnijuet A, Kraus J, Henkels MD, Muclchen AM, Loper JE. 1995. The sigma factor sigma s affects antibiotic production and biological control activity of Pseudomonas fluorescens Pf-5. Proc. Natl. Acad. Sci. U. S. A. 92:12255–12259. http://dx.doi.org/10.1073/pnas.92.26.12255.

37. Rosenberg K, Bertaux J, Krome K, Hartmann A, Scheu S, Bonkowski M. 2009. Soil amoeba rapidly change bacterial community composition in the rhizosphere of Arabidopsis thaliana. ISME J. 3:675–684. http://dx.doi.org/10.1038/ismej.2009.11.

38. Ronn R, McCaig AE, Griffiths BS, Prosser JL. 2002. Impact of protoplasts grazed on bacterial community structure in soil microcosms. Appl. Environ. Microbiol. 68:6094–6105. http://dx.doi.org/10.1128/AEM.68 .12.6094-6105.2002.

39. Umio S, Kawanishi T, Kamishita T, Mine Y, January 1987. Antifungal composition employing pyrrolinrin in combination with an imidazole compound. US patent 4636520.

40. Fuller AT, Mellows G, Woolford M, Banks GT, Barrow KD, Chain EB. 1971. Pseudomonas aeruginosa, an antibiotic produced by Pseudomonas fluorescens. Nature 234:416–417. http://dx.doi.org/10.1038/234416a0.

41. Bork K, Brauers J, Kresken M. 1989. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections—an open multicentre trial. Br. J. Clin. Pract. 43:284–288.

42. Stock LL, Lee MM, Rutan RL, Desai MH, Robson MC, Herndon DN, Hedges JP. 1990. Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci. J. Burn Care Rehabil. 11:454–459. http://dx.doi.org/10.1097/00004630-199010000-00015.

43. Neilands JB. 1981. Iron absorption and transport in microorganisms. Annu. Rev. Nutr. 1:27–46. http://dx.doi.org/10.1146/annurev.nutr.01.070181.00015w.

44. Marchi M, Boutin M, Gazengel K, Riske C, Gauthier JP, Guillem-Erckelboudt AY, Lebreton L, Barret M, Daval S, Sarnijuet A. 2013. Genomic analysis of the biocontrol strain Pseudomonas fluorescens Pf29Arp with evidence of T3SS and T6SS gene expression on plant roots. Genomic analysis of the biocontrol strain Pseudomonas fluorescens CHA0 shows increased ability in biofilm formation on mycorrhizal and nonmycorrhizal carrot roots. Mol. Plant Microbe Interact. 14:252–260. http://dx.doi.org/10.1094/MPMI.2011.14.2.255.

45. O’Toole GA, Kolter R. 1998. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signaling pathways: a genetic analysis. Mol. Microbiol. 28:449–461. http://dx.doi.org/10.1046/j.1365-2958.1998.00797.x.

46. Baum MM, Kaimovic A, O’Keeffe T, Pushtita R, McDonald K, Wu S, Webster P. 2009. Characterization of structures in biofilms formed by a Pseudomonas fluorescens isolated from soil. BMC Microbiol. 9:103. http://dx.doi.org/10.1186/1471-2180-9-103.

47. Chapalain A, Rossignon G, Lesouhaitier O, Merieau A, Gruffaz C, Guerillon J, Meyer JM, Orange N, Feuilloley MG. 2008. Comparative study of 7 fluorescent pseudomonad clinical isolates. Can. J. Microbiol. 54:19–27. http://dx.doi.org/10.1139/W07-110.

48. Rossignon G, Spérandio D, Guerillon J, Cuclairoir Poc C, Soum-Soutera E, Orange N, Feuilloley MG, Merieau A. 2009. Phenotypic variation in the Pseudomonas fluorescens clinical strain MFN1032. Res. Microbiol. 160:337–344. http://dx.doi.org/10.1016/j.resmic.2009.04.004.

49. Spérandio D, Decoin V, Latour X, Mijouin I, Hillion M, Feuilloley MG, Orange N, Merieau A. 2012. Virulence of the Pseudomonas fluorescens clinical strain MFN1032 towards Dicyostelium discoideum and macrophages in relation withtype III secretion system. BMC Microbiol. 12:223. http://dx.doi.org/10.1186/1471-2180-12-223.

50. Almeida LA, Araujo R. 2013. Highlights on molecular identification of closely related species. Infect. Genet. Evol. 13:67–75. http://dx.doi.org/10.1016/j.meegde.2012.08.011.

51. Konstantinidis KT, Ramette A, Tiedje JM. 2006. Toward a more robust assessment of intraspecies diversity, using fewer genetic markers. Appl. Environ. Microbiol. 72:7286–7293. http://dx.doi.org/10.1128/AEM.01398-06.

52. Moore ERB, Tindall BJ, Dos Santos VAPM, Pieper DH, Ramos JL, Palleron NJ. 2006. Nonmedical: Pseudomonas, p 646–703. In Dworkin M, Falkow S, Rosenberg E, Schleifer K-H, Stackebrandt E (ed), Prokaryotes: a handbook on the biology of bacteria, vol 6, 3rd ed. Springer, New York, NY.

53. Howell C, Stipanovic R. 1980. Suppression of Pythium ultimum-induced damping-off of cotton seedlings by Pseudomonas fluorescens and its antibiotic, pyoluteorin. Phytopathology 70:712–715. http://dx.doi.org/10.1094/Phyto-70-712.

54. De Souza JT, De Beer M, De Ward P, Van Beek TA, Raaijmakers JM. 2003. Biochemical, genetic, and zoosporidial properties of cyclic lipo-peptide surfactants produced by Pseudomonas fluorescens. Appl. Environ. Microbiol. 69:7161–7172. http://dx.doi.org/10.1128/AEM.69.12 .7161-7172.2003.

55. Valverde C, Heeb S, Keel C, Haas D. 2003. RsmY, a small regulatory RNA, is required in concert with RsmZ for GacA-dependent expression

P. fluorescens Microbiology, Genomics, and Disease

October 2014 Volume 27 Number 4 cmr.asm.org
of biocontrol traits in Pseudomonas fluorescens CHA0. Mol. Microbiol. 50:1361–1379. http://dx.doi.org/10.1046/j.1365-2958.2003.03774.x.

66. Cosson P, Soldati T. 2008. Eat, kill or die: when amoeba meets bacteria. Curr. Opin. Microbiol. 11:271–276. http://dx.doi.org/10.1016/j.mib.2008.05.005.

67. Klaenhammer TR, Ward MK, Raney DE. 1954. Two simple media for the demonstration of pyocyanin and fluorescin. J. Lab. Clin. Med. 44:301–307.

68. Lowbury EJ, Collins AG. 1955. The use of a new cetrimide product in a selective medium for Pseudomonas pyocyanea. J. Clin. Pathol. 8:47–48. http://dx.doi.org/10.1046/j.1365-2753.1955.tb04045.x.

69. Bunker ST, Bates TC, Oliver JD. 2004. Effects of temperature on detection of plasmid or chromosomally encoded gfp- and lux-labeled Pseudomonas fluorescens in soil. Environ. Biores. 3:83–90. http://dx.doi.org/10.1051/ebr:2004008.

70. Oliver J. 1993. Formation of viable but nonculturable cells, p 239–272. In Kjelleberg S (ed), Starvation in bacteria. Plenum Press, New York, NY.

71. Rowan N. 2004. Viable but non-culturable forms of food and waterborne bacteria: quo vadis? Trends Food Sci. Technol. 15:462–467. http://dx.doi.org/10.1016/j.tifs.2004.02.009.

72. Oliver JD. 1995. The viable but non-culturable state in bacteria. J. Microbiol. 43(Spec Issue):93–100.

73. Mulet M, Lalucat J, Garcia-Valdes E. 2010. DNA sequence-based analysis of the Pseudomonas species. Environ. Microbiol. 12:1513–1530. http://dx.doi.org/10.1111/j.1462-2920.2010.02181.x.

74. Peix A, Ramirez-Bahena MH, Velazquez E. 2009. Historical evolution and current status of the taxonomy of genus Pseudomonas. Infect. Genet. Evol. 9:1132–1147. http://dx.doi.org/10.1016/j.meegid.2009.08.001.

75. Anzai Y, Kim H, Park JY, Wakabayashi H, Oyaizu H. 2000. Phylogenetic affiliation of the pseudomonads based on 16S rRNA sequence. Int. J. Syst. Evol. Microbiol. 50:1963–1589. http://dx.doi.org/10.1099/00207713-50-4-15463.

76. Pallaroni NJ. 2010. The Pseudomonas story. Environ. Microbiol. 12:1377–1383. http://dx.doi.org/10.1111/j.1462-2920.2009.02041.x.

77. Pallaroni NJ. 2008. The road to the taxonomy of Pseudomonas, p 1–18. In Cornelis P (ed), Pseudomonas. Genomics and molecular biology. Caister Academic Press, Norfolk, United Kingdom.

78. Moore ERB, Mau M, Arnscheidt A, Botter JC, Hutson RA, Collins MD, Peer YVD, Wachtet RD, Timmis KN. 1996. The determination and comparison of the 16S rRNA gene sequences of species of the genus Pseudomonas (sensus stricto) and estimation of the natural intragenic relationships. Syst. Appl. Microbiol. 19:478–492.

79. Yamamoto S, Kasai H, Arnold DL, Jackson RW, Vivian A, Harayama S. 2002. Phylogeny of the genus Pseudomonas: intragenic structure reconstructed from the nucleotide sequences of gyrB and rpoD genes. Microbiology 148:2385–2394.

80. Urwin R, Maiden MC. 2003. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol. 11:479–487. http://dx.doi.org/10.1016/S0928-8244(03)00053-4.

81. Chan MS, Maiden MC, Spratt BG. 2001. Database-driven multi locus sequence typing (MLST) of bacterial pathogens. Bioinformatics 17:1077–1083. http://dx.doi.org/10.1093/bioinformatics/17.11.1077.

82. Sullivan CB, Diggle MA, Clarke SC. 2005. Multilocus sequence typing: data analysis in clinical microbiology and public health. Mol. Biotechnol. 29:245–254. http://dx.doi.org/10.1385/MB:29:3:245.

83. Byun R, Elbourne LD, Lan R, Reeves PR. 1999. Evolutionary relationships of pathogenic clones of Vibrio cholerae by sequence analysis of four housekeeping genes. Infect. Immun. 67:1116–1124.

84. Savli H, Karadenizli J, Blomberg C, Browall S, Sjostrom K, Morfeldt E, Henrik-Normark B. 2008. Determination of accessory gene patterns pre-selection of biocontrol traits in Pseudomonas aeruginosa. J. Med. Microbiol. 57:89–101. http://dx.doi.org/10.1099/jmm.0.05132-0.

85. Katz H, Standlee DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol. Biol. Evol. 30:772–780. http://dx.doi.org/10.1093/molbev/mst010.

86. Katz H, Frith MC. 2012. Adding unaligned sequences into an existing alignment using MAFFT and LAST. Bioinformatics 28:3144–3146. http://dx.doi.org/10.1093/bioinformatics/bts578.

87. Katz H, Kuma K, Toh H, Miyata T. 2005. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 33:511–518. http://dx.doi.org/10.1093/nar/gkj198.

88. Katz H, Misawa K, Kuma K, Miyata T. 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30:3059–3066. http://dx.doi.org/10.1093/nar/gkf436.

89. Botha P, Archer I, Anderson LR, Lordan JD, Dark JH, Corris PA, Gould K, Fisher AJ. 2008. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 85:771–774. http://dx.doi.org/10.1097/TP.0b013e31816651d1.

90. Ros R, Vanaudenaerde BM, Geudens N, DuPont LJ, Van Raemdonck DE, Verleden GM. 2008. Pseudomonas aeruginosa airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur. Respir. J. 31:1034–1039. http://dx.doi.org/10.1183/09031988.04012607.

91. Gottesle B, Mattner F, Weissbrodt H, Dierich M, Fuehner T, Stueber M, Simon A, Welte T. 2009. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir. Med. 103:743–749. http://dx.doi.org/10.1016/j.rmed.2008.11.015.

92. Willner DL, Hugenholz P, Yerovich ST, Tan ME, Daly JN, Lachner N, Hopkins PM, Chambers DC. 2013. Re-establishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am. J. Respir. Crit. Care Med. 187:640–647. http://dx.doi.org/10.1164/rccm.201209-1680OC.

93. Enderby B, Smith D, Carroll W, Lenney W. 2009. Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis. Pediatr. Pulmonol. 44:142–147. http://dx.doi.org/10.1002/ppul.20963.

94. Laville J, Blumer C, Von Schroeter G, Gracia V, Defago F, Keel C, Haas D. 1998. Characterization of the hcaABC gene cluster encoding hydrocyanic acid synthase and anaerobic regulation by ANR in the strictly aerobic biocontrol agent Pseudomonas fluorescens CHAO. J. Bacteriol. 180:317–319.

95. Partida-Martinez LP, Hertweck C. 2005. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature 437:884–888. http://dx.doi.org/10.1038/nature03997.

96. Tekeda R. 1958. Pseudomonas fluorescens. I. Pyoluteorin, a new chlorine-containing pigment produced by Pseudomonas aeruginosa. Hakko Kogaku Zasshi 36:281–290.

97. Ligon JM, Hill DS, Hammer PE, Torzewitz NR, Hofmann D, Clinical Microbiology Reviews.
Defago G.

668–678::AID-PS186

89:

1977. Novel small RNA-encoding genes in the intergenic

regions of Escherichia coli. Microbiology 171:1–10. http://dx.doi.org/10.1099/mic.0.17101-0.

O'Toole GA, Sondermann H.

9:

mediated inside-out signaling controlling periplasmic proteolysis. PLoS Pathog 8:1–10. http://dx.doi.org/10.1371/journal.ppat.1002735.

Kempf H, Pee H.

3:

October 2014 Volume 27 Number 4 cmr.asm.org

P. fluorescens Microbiology, Genomics, and Disease

492.

http://dx.doi.org/10.1128/AEM.66.2.487-492.2000.

Kempf H, Pee H.

9:

1994. Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. J. Bacteriol. 176:269–275. http://dx.doi.org/10.1128/JB.176.1.269–275.1994.

Daneshvar A, Truelstrup H.

11:

1994. Novel small RNA-encoding genes in the intergenic regions of Escherichia coli. Microbiology 171:1–10. http://dx.doi.org/10.1099/mic.0.17101-0.

Keyack A, Vázquez C, Deadpool B, Haas D, Schreiber F.

13:

2003. Small RNAs in bacteria: diverse regulators of gene expression. Curr. Opin. Microbiol. 6:111–117. http://dx.doi.org/10.1016/S1369-5270(03)00054-3.

Pessi A, Bassler BL.

7:

2001. Molecular basis of plant growth promotion and biocontrol by rhizobacteria. Curr. Opin. Plant Biol. 4:343–350. http://dx.doi.org/10.1016/S1369-5266(00)00183-7.

Whitehead NA, Barnard AM, Slater H, Simpson NJ, Salmond GP. 2001. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol. Rev. 25:365–404. http://dx.doi.org/10.1111/j.1579-7222.2001.tb00583.x.

El-Sayed AK, Hothersall J, Thomas CM. 2001. Quorum-sensing-dependent regulation of biosynthesis of the polyketide antibiotic mupirocin in Pseudomonas fluorescens NCIMB 10586. Microbiology 147:2127–2139.

Laue BE, Jiang, Y, Chhabra SR, Jacob S, Stewart GS, Downie S, Simpson TJ, Willis CL, Simpson NJ, Salmond GP. 2001. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol. Rev. 25:365–404. http://dx.doi.org/10.1111/j.1579-7222.2001.tb00583.x.

Navarro MV, Newell PD, Krasteva PV, Chatterjee D, Madden DR, Blumer C, Haas D, McSweeny S, Arnold DL, Moon CD, Timms-Wilson T, Spiers AJ. 2001. Molecular basis of plant growth promotion and biocontrol by rhizobacteria. Curr. Opin. Plant Biol. 4:343–350. http://dx.doi.org/10.1016/S1369-5266(00)00183-7.

Whitehead NA, Barnard AM, Slater H, Simpson NJ, Salmond GP. 2001. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol. Rev. 25:365–404. http://dx.doi.org/10.1111/j.1579-7222.2001.tb00583.x.

El-Sayed AK, Hothersall J, Thomas CM. 2001. Quorum-sensing-dependent regulation of biosynthesis of the polyketide antibiotic mupirocin in Pseudomonas fluorescens NCIMB 10586. Microbiology 147:2127–2139.

Laue BE, Jiang, Y, Chhabra SR, Jacob S, Stewart GS, Downie S, Simpson TJ, Willis CL, Simpson NJ, Salmond GP. 2001. Quorum-sensing in Gram-negative bacteria. FEMS Microbiol. Rev. 25:365–404. http://dx.doi.org/10.1111/j.1579-7222.2001.tb00583.x.

Navarro MV, Newell PD, Krasteva PV, Chatterjee D, Madden DR, O’Toole GA, Sondermann H. 2011. Structural basis for c-di-GMP-mediated inside-out signaling controlling periplasmic proteolysis. PLoS Biol. 9:e1000588. http://dx.doi.org/10.1371/journal.pbio.1000588.

Newell PD, Yoshioka S, Hvorcely KL, Monds RD, O’Toole GA. 2011. Systematic analysis of diguanylate cyclases that promote biofilm forma-
tion by Pseudomonas fluorescens Pf-0–1. J. Bacteriol. 193:4685–4698. http://dx.doi.org/10.1128/JB.03483-11.

144. Newell PD, Boyd CD, Sondermann H, O'Toole GA. 2011. A c-di-GMP effector system controls cell adhesion by inside-out signaling and surface protein cleavage. PLoS Biol. 9:e1000587. http://dx.doi.org/10.1371/journal.pbio.009.e0587.

145. Rosqvist R, Magnusson KE, Wolf-Watz H. 1994. Target cell contact triggers expression and polarized transfer of Yersinia YopE cytotoxin into mammalian cells. EMBO J. 13:964–972.

146. Sory MP, Cornelis GR. 1994. Translocation of a hybrid YopE-adenylate cyclase from Yersinia enterocolitica into HeLa cells. Mol. Microbiol. 14:583–594. http://dx.doi.org/10.1111/j.1365-2958.1994.tb02191.x.

147. He SY, Nomura K, Whittam TS. 2004. Type III protein secretion mechanism in mammalian and plant pathogens. Biochim. Biophys. Acta. 1694:181–206. http://dx.doi.org/10.1016/j.bbamcr.2004.03.011.

148. Lindgren PB, Peet RC, Panopoulos NJ. 1986. Gene cluster of Pseudomonas syringae pv. "phaseolicola" controls pathogenicity of bean plants and hypersensitivity of nonhost plants, J. Bacteriol. 168:512–522.

149. Gopalan S, Wei W, He SY. 1996. hsp gene-dependent induction of hin1: a plant gene activated rapidly by both harpins and the AvrPto gene-mediated signal. Plant J. 10:591–600. http://dx.doi.org/10.1104/jr.193-313X.1996.1004051X.

150. Tang X, Frederick RD, Zhou J, Halterman DA, Jia Y, Martin GB. 1996. Initiation of plant disease resistance by physical interaction of AvrPto and Pto kinase. Science 274:2060–2063. http://dx.doi.org/10.1126/science.274.5295.2060.

151. Scofield SR, Tobias CM, Rathjen JP, Chang JH, Lavelle DT, Michelmore RW, Staskawicz BJ. 2000. Type III protein secretion activity of type III system-secreted proteins leads to oncosis of Pseudomonas fluorescens. PLoS One 7:e24651. http://dx.doi.org/10.1371/journal.pone.0024651.

152. Rosqvist G, Meriau J, Guerillon J, Veron W, Lesoubhier O, Feuilleloy MG, Orange N. 2008. Involvement of a phospholipase C in the hemolytic activity of a clinical strain of Pseudomonas fluorescens. BMC Microbiol. 8:189. http://dx.doi.org/10.1186/1471-2180-8-189.

153. Sperandio V, Choi C, Allain J, Foursy C, Meriau A. 2003. Bioinformatics correctly identifies many type III secretion substrates in the plant pathogen Pseudomonas fluorescens. BMC Microbiol. 3:44. http://dx.doi.org/10.1186/1471-2180-3-44.

154. Engel J, Balachandran P. 2009. Role of Pseudomonas aeruginosa type III effectors in disease. Curr. Opin. Microbiol. 12:231–237. http://dx.doi.org/10.1016/j.mib.2009.12.007.

155. Shanahan P, O'Sullivan DJ, Simpson P, Glennon JD, O'Farra G. 1992. Isolation of 2,4-diacetylphloroglucinol from a fluorescent pseudomonad and investigation of physiological parameters influencing its production. Appl. Environ. Microbiol. 58:353–358.

156. Cronin D, Moenne-Loccoz Y, Fenton A, Dunne C, Dowling DN, O'Gara F. 1997. Role of 2,4-diacetylphloroglucinol in the interactions of the biocontrol pseudomonad strain F113 with the potato cyst nematode Globodera rostochiensis. Appl. Environ. Microbiol. 63:1357–1361.

157. Barahona E, Navazo A, Martinez-Granero F, Zea-Bonilla T, Perez-Jimenez RM, Martin M, Rivilla R. 2011. Pseudomonas fluorescens F113 mutant with enhanced competitive colonization ability and improved biocontrol activity against fungal root pathogens. Appl. Environ. Microbiol. 77:5412–5419. http://dx.doi.org/10.1128/AEM.00320-11.

158. Fenton AM, Steadley D, Crowley J, O'Callaghan M, O'Gara F. 1992. Exploitation of gene(s) involved in 2,4-diacetylphloroglucinol biosynthesis to confer a new biocontrol capability to a Pseudomonas fluorescens. Appl. Environ. Microbiol. 58:3873–3878.

159. Pernthaler J. 2005. Predation on prokaryotes in the water column and its ecological implications. Nat. Rev. Microbiol. 3:537–546. http://dx.doi.org/10.1038/nrmicro1180.
227. Barton Paulsen

228. Banowetz GM, Azevedo MD, Armstrong DJ, Halgren AB, Mills DI. 2008. Germination-arrest factor (GAF): biological properties of a novel, naturally-occurring herbicide produced by selected isolates of rhizosphere bacteria. Biol. Control 46:380–390. http://dx.doi.org/10.1016/j.biocontrol.2008.04.016.

225. Kimbrel JA, Givan SA, Halgren AB, Creason AL, Mills DI, Banowetz GM, Armstrong DJ, Chang JH. 2010. An improved, high-quality draft genome sequence of the germination-arrest factor-producing *Pseudomonas fluorescens* WH6. BMC Genomics 11:522. http://dx.doi.org/10.1186/1471-2164-11-522.

224. Pierson EA, Weller DM. 1994. Use of mixtures of fluorescent pseudomonads to suppress take-all and improve the growth of wheat. Phytopathology 84:940–947. http://dx.doi.org/10.1094/Phyto-84-940.

229. Stutz EW, Défago G, Kern H. 1986. Naturally occurring fluorescent pseudomonads involved in suppression of black root rot of tobacco. Phytopathology 76:181–185. http://dx.doi.org/10.1094/Phyto-76-181.

223. Brittan S. Scales received her Master’s in Public Health in Infectious Diseases and Vaccinology from the University of Berkeley, Berkeley, CA. She is currently a Ph.D. candidate in Microbiology and Immunology at the University of Michigan Medical School. She is also a member of the American Academy of Microbiology. His research interests include understanding the microbiome community dynamics during cystic fibrosis.

226. Ramette A, Frapolli M, Fischer-Le Saux M, Gruffaz C, Meyer JM, Défago G, Sutra L, Moenne-Loccoz Y. 2011. Pseudomonas protegens sp. nov., widespread plant-protecting bacteria producing the biocontrol compounds 2,4-diacetylphloroglucinol and pyoluteorin. Syst. Appl. Microbiol. 34:180–188. http://dx.doi.org/10.1016/j.syam.2010.10.005.

222. Pierson EA, Weller DM. 1998. Natural plant protection by 2,4-diacetylphloroglucinol-producing *Pseudomonas* spp. in take-all decline soils. Mol. Plant Microbe Interact. 11:144–152.

221. Viktorov H, Zhou L, Schneider DJ, Cartinhour SW, Nelson WC, Weidman J, Pf-5. Nat. Biotechnol. 23:873–878. http://dx.doi.org/10.1038/nbt1110.

228. Banowetz GM, Azevedo MD, Armstrong DJ, Halgren AB, Mills DI. 2008. Germination-arrest factor (GAF): biological properties of a novel, naturally-occurring herbicide produced by selected isolates of rhizosphere bacteria. Biol. Control 46:380–390. http://dx.doi.org/10.1016/j.biocontrol.2008.04.016.

225. Kimbrel JA, Givan SA, Halgren AB, Creason AL, Mills DI, Banowetz GM, Armstrong DJ, Chang JH. 2010. An improved, high-quality draft genome sequence of the germination-arrest factor-producing *Pseudomonas fluorescens* WH6. BMC Genomics 11:522. http://dx.doi.org/10.1186/1471-2164-11-522.

224. Pierson EA, Weller DM. 1994. Use of mixtures of fluorescent pseudomonads to suppress take-all and improve the growth of wheat. Phytopathology 84:940–947. http://dx.doi.org/10.1094/Phyto-84-940.

229. Stutz EW, Défago G, Kern H. 1986. Naturally occurring fluorescent pseudomonads involved in suppression of black root rot of tobacco. Phytopathology 76:181–185. http://dx.doi.org/10.1094/Phyto-76-181.

223. Brittan S. Scales received her Master’s in Public Health in Infectious Diseases and Vaccinology from the University of Berkeley, Berkeley, CA. She is currently a Ph.D. candidate in Microbiology and Immunology at the University of Michigan Medical School. She is also a member of the American Academy of Microbiology. His research interests include understanding the microbiome community dynamics during cystic fibrosis.

226. Ramette A, Frapolli M, Fischer-Le Saux M, Gruffaz C, Meyer JM, Défago G, Sutra L, Moenne-Loccoz Y. 2011. Pseudomonas protegens sp. nov., widespread plant-protecting bacteria producing the biocontrol compounds 2,4-diacetylphloroglucinol and pyoluteorin. Syst. Appl. Microbiol. 34:180–188. http://dx.doi.org/10.1016/j.syam.2010.10.005.

222. Pierson EA, Weller DM. 1998. Natural plant protection by 2,4-diacetylphloroglucinol-producing *Pseudomonas* spp. in take-all decline soils. Mol. Plant Microbe Interact. 11:144–152.

221. Viktorov H, Zhou L, Schneider DJ, Cartinhour SW, Nelson WC, Weidman J, Pf-5. Nat. Biotechnol. 23:873–878. http://dx.doi.org/10.1038/nbt1110.

228. Banowetz GM, Azevedo MD, Armstrong DJ, Halgren AB, Mills DI. 2008. Germination-arrest factor (GAF): biological properties of a novel, naturally-occurring herbicide produced by selected isolates of rhizosphere bacteria. Biol. Control 46:380–390. http://dx.doi.org/10.1016/j.biocontrol.2008.04.016.

225. Kimbrel JA, Givan SA, Halgren AB, Creason AL, Mills DI, Banowetz GM, Armstrong DJ, Chang JH. 2010. An improved, high-quality draft genome sequence of the germination-arrest factor-producing *Pseudomonas fluorescens* WH6. BMC Genomics 11:522. http://dx.doi.org/10.1186/1471-2164-11-522.